Buy Cetirizine film-coated tablets 10 mg No. 20 in pharmacies

Mode of application

Use internally with 1 glass of liquid.

Food intake does not affect the amount of absorption of cetirizine, although it somewhat slows down this process.

Adults and children over 6 years of age: 10 mg 1 tablet 1 time per day.

The drug can be used at an initial dose of 5 mg if it is sufficient to control symptoms.

The course of treatment is determined by the doctor and depends on the course and duration of the disease and the individual sensitivity of the patient.

There is no need to reduce the dose in elderly patients unless they have impaired renal function.

Cetirizine Sandoz, 10 pcs., 10 mg, film-coated tablets

Pharmacodynamics:

Cetirizine has a pronounced antiallergic effect. It has virtually no sedative effect in pharmacologically active doses, is a selective antagonist of H1-histamine receptors and has virtually no anticholinergic and antiserotonin effects, prevents the development and facilitates the course of allergic reactions. Has antipruritic and antiexudative effect. Affects the early stage of allergic reactions, and also reduces the migration of inflammatory cells; inhibits the release of mediators involved in a late allergic reaction. Reduces capillary permeability, prevents the development of tissue edema, relieves spasm of smooth muscles. Eliminates skin reactions to the introduction of histamine, specific allergens, as well as to cooling (with cold urticaria). Cetirizine significantly reduces the hyperreactivity of the bronchial tree that occurs in response to the release of histamine in patients with bronchial asthma. The therapeutic effect of the drug appears on average 60 minutes after administration. During the course of treatment, tolerance does not develop.

Pharmacokinetics:

Absorption: after oral administration, cetirizine is quickly and well absorbed from the gastrointestinal tract. The maximum concentration level is determined after approximately 40 - 60 minutes. Food intake does not have a significant effect on the amount of absorption, but in this case the rate of absorption is slightly reduced. Distribution: cetirizine is approximately 93% bound to plasma proteins. The volume of distribution (Vd) is low (0.5 l/kg), the drug does not penetrate into the cell. The drug does not penetrate the blood-brain barrier. Metabolism: Cetirizine is poorly metabolized in the liver to form an inactive metabolite. With 10-day use at a dose of 10 mg, no accumulation of the drug is observed. Excretion: approximately 70% occurs by the kidneys, mainly unchanged. The systemic clearance is about 54 ml/min. After a single dose, the half-life is about 10 hours. In children aged 2 to 12 years, the half-life decreases to 5-6 hours. In case of impaired renal function (creatinine clearance below 11-31 ml/min) and in patients on hemodialysis (creatinine clearance less than 7 ml/min), the half-life increases 3 times, clearance decreases by 70%. Against the background of chronic diseases and in elderly patients, there is an increase in the half-life by 50% and a decrease in clearance by 40%. Hemodialysis is ineffective.

Features of application

Pregnant

Cetirizine passes into breast milk in concentrations ranging from 25 to 90% of plasma concentrations, depending on the period of time after administration of the drug.

Therefore, women who are breastfeeding should use cetirizine with caution.

Drivers

Patients who drive vehicles, are involved in potentially hazardous work, or maintain mechanized equipment should not exceed the recommended doses and should take into account their own body's reaction to the drug.

In sensitive patients, concomitant use of the drug with alcohol or other CNS depressants may cause additional impairment of attention when performing potentially hazardous work.

For children

The drug should be used in children over 6 years of age.

Cetirizine-Teva tablets 10 mg 20 pcs. in Lipetsk

Pharmacological action: Cetirizine is a metabolite of hydroxyzine, belongs to the group of competitive histamine antagonists and blocks H1-histamine receptors. In addition to the antihistamine effect, cetirizine prevents the development and alleviates the course of allergic reactions: at a dose of 10 mg once or twice a day, it inhibits the late phase of eosinophil aggregation in the skin and conjunctiva of patients with allergic reactions.

Pharmacokinetics:

The pharmacokinetic parameters of cetirizine when used in doses from 5 to 60 mg change linearly.

Suction.

The maximum concentration in blood plasma is reached after 1±0.5 hours and is 300 ng/ml. Various pharmacokinetic parameters, such as maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC), are homogeneous. Food intake does not affect the complete absorption of cetirizine, although its rate decreases. The bioavailability of various dosage forms of cetirizine (solution, capsules, tablets) is comparable.

Distribution.

Cetirizine is 93±0.3% bound to plasma proteins. The apparent volume of distribution (Vd) is 0.5 l/kg. Cetirizine does not affect the protein binding of warfarin.

Metabolism

. Cetirizine does not undergo extensive first-pass metabolism.

Excretion.

The half-life (T1/2) is approximately 10 hours. When taking the drug at a daily dose of 10 mg for 10 days, no accumulation of cetirizine was observed. Approximately 2/3 of the dose taken is excreted unchanged in the urine.

Elderly patients.

In 16 elderly individuals, with a single dose of 10 mg of the drug, T1/2 was 50% higher, and clearance was 40% lower compared to non-elderly individuals. The decreased clearance of cetirizine in elderly patients is likely due to decreased renal function in this category of patients.

Patients with renal failure.

In patients with mild renal failure (creatinine clearance (CC) > 40 ml/min), pharmacokinetic parameters are similar to those in healthy volunteers with normal renal function. In patients with moderate renal failure and in patients on hemodialysis (creatinine clearance <7 ml/min), when taking the drug orally at a dose of 10 mg, T1/2 is extended by 3 times, and total clearance is reduced by 70% relative to healthy volunteers with normal renal function. For patients with moderate or severe renal failure, an appropriate change in the dosage regimen is required. Cetirizine is practically not removed from the body during hemodialysis.

Patients with liver failure.

In patients with chronic liver diseases (hepatocellular, cholestatic and biliary cirrhosis), with a single dose of 10 or 20 mg, T1/2 increases by approximately 50%, and clearance decreases by 40% compared to healthy subjects. Dose adjustment is only necessary if the patient with hepatic insufficiency also has concomitant renal insufficiency.

Children.

T1/2 in children from 6 to 12 years is 6 hours, from 2 to 6 years - 5 hours, from 6 months to 2 years - reduced to 3.1 hours.

Overdose

Symptoms observed after overdose of cetirizine are mainly related to the effects on the central nervous system or effects that may indicate anticholinergic effects.

Side effects reported after taking a dose greater than at least 5 times the recommended daily dose include: confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis, itching, restlessness, sedation, drowsiness, stupor, tachycardia. tremor, urinary retention.

Side effects

Violations such as:

• From the blood and lymphatic system, thrombocytopenia is very rare.
• On the part of the immune system, hypersensitivity and anaphylactic shock are rare.
• Metabolism and nutrition: increased appetite.
• From the mental side: infrequently agitation, rarely aggressiveness, confusion, depression, hallucinations, insomnia, very rarely nervous tics, suicidal thoughts.
• From the nervous system: infrequently paresthesia, rarely convulsions, very rarely dysgeusia, fainting, tremor, dystonia, dyskinesia, amnesia, memory impairment.
• From the organs of vision: impaired accommodation of the eye, blurred vision, involuntary movements of the eyeball.
• On the part of the hearing organs, vertigo.
• Cardiac disorders rarely include tachycardia.
• From the gastrointestinal tract, diarrhea is uncommon.
• From the digestive system, liver dysfunction is rare.
• From the skin and subcutaneous tissue: itching, rash, urticaria, angioedema, persistent drug-induced erythema, acute generalized exanthematous pustulosis.
• From the urinary system: very rarely dysuria, enuresis, urinary retention.

Buy Cetirizine film-coated tablets 10 mg No. 20 in pharmacies

Trade name:

Cetirizin-Teva

International nonproprietary name:

cetirizine

Dosage form:

film-coated tablets

Compound

1 tablet contains:

active substance

cetirizine dihydrochloride 10.00 mg;

Excipients:

microcrystalline cellulose (Avicel PH 102) 40.00 mg, lactose monohydrate 63.50 mg, colloidal silicon dioxide (colloidal silicon dioxide anhydrous) 0.50 mg, magnesium stearate 1.00 mg; shell Opadry OY-GM-28900 white: hypromellose (E464) 0.94 mg, polydextrose 0.94 mg, titanium dioxide (E171) 0.94 mg, macrogol-4000 (polyethylene glycol-4000) 0.18 mg.

Description

Biconvex oblong tablets, film-coated, white or almost white. On one side there is an engraving “C10”, on the other there is a dividing line. On a cross section, the core is white or almost white. The tablets must be free of cracks and chips.

Pharmacotherapeutic group:

antiallergic agent H1-histamine receptor blocker

Pharmacological properties

Pharmacodynamics

Cetirizine is a metabolite of hydroxyzine, belongs to the group of competitive histamine antagonists and blocks H1-histamine receptors.

In addition to the antihistamine effect, cetirizine prevents the development and alleviates the course of allergic reactions: at a dose of 10 mg once or twice a day, it inhibits the late phase of eosinophil aggregation in the skin and conjunctiva of patients with allergic reactions.

Clinical efficacy and safety. Studies in healthy volunteers have shown that cetirizine at doses of 5 or 10 mg significantly inhibits the rash and redness response to high concentrations of histamine in the skin, but the correlation with efficacy has not been established.

A 6-week placebo-controlled study involving 186 patients with allergic rhinitis and concomitant mild to moderate asthma showed that cetirizine 10 mg once daily reduced rhinitis symptoms and did not affect pulmonary function.

The results of this study confirm the safety of cetirizine in patients suffering from allergies and mild to moderate bronchial asthma.

A placebo-controlled study showed that taking cetirizine at a dose of 60 mg per day for 7 days did not cause a clinically significant prolongation of the QT interval.

Taking cetirizine at the recommended dose showed an improvement in the quality of life of patients with year-round and seasonal allergic rhinitis.

Children. In a 35-day study in patients aged 5-12 years, there was no evidence of resistance to the antihistamine effect of cetirizine. The normal skin reaction to histamine was restored within three days after discontinuation of the drug with repeated use.

Pharmacokinetics

The pharmacokinetic parameters of cetirizine when used in doses from 5 to 60 mg change linearly.

Absorption. The maximum concentration in blood plasma is reached after 1±0.5 hours and is 300 ng/ml.

Various pharmacokinetic parameters, such as maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC), are homogeneous.

Food intake does not affect the complete absorption of cetirizine, although its rate decreases. The bioavailability of various dosage forms of cetirizine (solution, capsules, tablets) is comparable.

Distribution.

Cetirizine is 93±0.3% bound to plasma proteins. The apparent volume of distribution (Vd) is 0.5 l/kg. Cetirizine does not affect the protein binding of warfarin.

Metabolism: Cetirizine does not undergo extensive primary metabolism.

Elimination: The half-life (T1/2) is approximately 10 hours.

When taking the drug at a daily dose of 10 mg for 10 days, no accumulation of cetirizine was observed.

Approximately 2/3 of the dose taken is excreted unchanged in the urine.

Elderly patients. In 16 elderly individuals, with a single dose of 10 mg of the drug, T1/2 was 50% higher, and clearance was 40% lower compared to non-elderly individuals.

The decreased clearance of cetirizine in elderly patients is likely due to decreased renal function in this category of patients.

Patients with renal failure. In patients with mild renal failure (creatinine clearance (CC) > 40 ml/min), pharmacokinetic parameters are similar to those in healthy volunteers with normal renal function.

In patients with moderate renal failure and in patients on hemodialysis (creatinine clearance <7 ml/min), when taking the drug orally at a dose of 10 mg, T1/2 is extended by 3 times, and the total clearance is reduced by 70% relative to healthy volunteers with normal renal function.

For patients with moderate or severe renal failure, an appropriate change in the dosage regimen is required. Cetirizine is practically not removed from the body during hemodialysis.

Patients with liver failure. In patients with chronic liver diseases (hepatocellular, cholestatic and biliary cirrhosis), with a single dose of 10 or 20 mg, T1/2 increases by approximately 50%, and clearance decreases by 40% compared to healthy subjects. Dose adjustment is only necessary if the patient with hepatic insufficiency also has concomitant renal insufficiency.

Children. T1/2 in children from 6 to 12 years is 6 hours, from 2 to 6 years - 5 hours, from 6 months to 2 years - reduced to 3.1 hours.

Indications for use

Cetirizine dihydrochloride is indicated for use in adults and children 6 years of age and older to relieve:

- nasal and ocular symptoms of year-round (persistent) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis: itching, sneezing, nasal congestion, rhinorrhea, lacrimation, conjunctival hyperemia; - symptoms of chronic idiopathic urticaria.

Contraindications

- Hypersensitivity to cetirizine, hydroxyzine or piperazine derivatives, as well as other components of the drug. — End-stage renal failure (creatinine clearance <10 ml/min). - Children under 6 years of age (for this dosage form). - Pregnancy. — Hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.

Carefully

In patients:

— with chronic renal failure (with creatinine clearance > 10 ml per minute, dosage regimen adjustment is required); - elderly (with an age-related decrease in glomerular filtration); - with epilepsy and increased convulsive readiness; — with predisposing factors to urinary retention (see section “Special instructions”); - during breastfeeding.

Use during pregnancy and breastfeeding

Pregnancy

An analysis of prospective data from more than 700 cases of pregnancy outcomes revealed no cases of malformations, embryonic or neonatal toxicity with a clear cause-and-effect relationship.

Experimental studies on animals have not revealed any direct or indirect adverse effects of cetirizine on the developing fetus (including in the postnatal period), pregnancy and childbirth.

Adequate and strictly controlled clinical studies on the safety of the drug during pregnancy have not been conducted, therefore Cetirizine-Teva should not be used during pregnancy.

Breastfeeding period

Cetirizine is excreted in breast milk in concentrations representing from 25% to 90% of the drug concentration in the blood plasma, depending on the time after administration. During breastfeeding, it is used after consultation with a doctor, if the expected benefit to the mother outweighs the potential risk to the child.

Fertility

Available data on the effects on human fertility are limited, but no adverse effects on fertility have been identified.

Directions for use and doses

Inside. It is recommended to take the tablets with a glass of water without chewing, preferably in the evening.

For adults.

10 mg (1 tablet) once a day.

Elderly patients

There is no need to reduce the dosage in elderly patients unless renal function is impaired.

Patients with kidney failure

Since Cetirizine-Teva is excreted from the body mainly by the kidneys (see subsection “Pharmacokinetics”), if alternative treatment is not possible, in patients with renal failure, the dosage regimen of the drug should be adjusted depending on renal function (creatinine clearance).

Creatinine clearance (CC) for men can be calculated from serum creatinine concentration using the following formula:

CC for women can be calculated by multiplying the resulting value by a factor of 0.85.

Dosing in Adult Patients with Renal Impairment

Patients with liver dysfunction

In patients with impaired liver function alone, no dosage adjustment is required.

In patients with impairment of both liver and kidney function, dosage adjustment is recommended (see table above)

Children

Children from 6 to 12 years old

5 mg (1/2 tablet) twice daily

Children over 12 years old

10 mg (1 tablet) once daily

Sometimes an initial dose of 5 mg (1/2 tablet) may be sufficient if satisfactory control of symptoms is achieved.

For children with renal failure, the dose is adjusted taking into account CC and body weight.

If there is no improvement after treatment or new symptoms appear, you should consult your doctor.

Use the drug only according to the method of use and in the doses indicated in the instructions.

Side effect

Data obtained from clinical studies

Review

The results of clinical studies have demonstrated that the use of cetirizine in recommended doses leads to the development of minor undesirable effects on the central nervous system, including drowsiness, fatigue, dizziness and headache. In some cases, paradoxical stimulation of the central nervous system has been reported.

Despite the fact that cetirizine is a selective blocker of peripheral H1 receptors and has virtually no anticholinergic effects, isolated cases of difficulty urinating, disturbances of accommodation and dry mouth have been reported.

Liver dysfunction has been reported, accompanied by increased levels of liver enzymes and bilirubin. In most cases, adverse events resolved after discontinuation of cetirizine dihydrochloride.

List of adverse reactions

Data from double-blind, controlled clinical trials comparing cetirizine with placebo or other antihistamines given at recommended doses (10 mg once daily for cetirizine) in more than 3200 patients are available on which to conduct a reliable analysis safety data.

According to the results of the pooled analysis, in placebo-controlled studies with the use of cetirizine at a dose of 10 mg, the following adverse reactions were identified with a frequency of 1.0% or higher:

Although the incidence of somnolence in the cetirizine group was higher than that in the placebo group, most cases were mild or moderate in severity. When objectively assessed in other studies, it was confirmed that the use of cetirizine at the recommended daily dose in healthy young volunteers does not affect their daily activities.

Children

In placebo-controlled studies, the following adverse reactions were observed with an incidence of 1% or greater in children aged 6 months to 12 years:

Post-registration experience

In addition to the adverse events identified during clinical trials and described above, the following adverse reactions were observed during post-registration use of the drug.

Adverse reactions are systematized in accordance with the World Health Organization (WHO) Classification: very common (≥1/10); often (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000); very rare (<1/10000); frequency unknown (cannot be determined from available data).

From the blood and lymphatic system: very rarely - thrombocytopenia.

From the immune system: rarely - hypersensitivity reactions; very rarely - anaphylactic shock.

Metabolic and eating disorders: frequency unknown - increased appetite.

Mental disorders: infrequently - agitation; rarely - aggression, confusion, depression, hallucinations, sleep disturbance; very rarely - tic; frequency unknown - suicidal ideation, sleep disturbances (including nightmares).

From the nervous system: infrequently - paresthesia; rarely - convulsions; very rarely - taste perversion, dyskinesia, dystonia, fainting, tremor; frequency unknown - memory impairment, including amnesia, deafness.

From the organ of vision: very rarely - disturbance of accommodation, blurred vision, nystagmus; frequency unknown - vasculitis.

On the part of the hearing organs: frequency unknown - vertigo.

From the cardiovascular system: rarely - tachycardia.

From the digestive system: infrequently - diarrhea.

Hepatobiliary disorders: rarely - liver failure with changes in liver function tests (increased activity of transaminases, alkaline phosphatase, gamma-glutamyltransferase and bilirubin).

On the skin: infrequently - rash, itching; rarely - urticaria; very rarely - angioedema, persistent drug erythema; frequency unknown - acute generalized exanthematous pustulosis.

From the urinary system: very rarely - dysuria, enuresis; frequency unknown - urinary retention.

General disorders: infrequently - asthenia, malaise; rarely - peripheral edema.

Research: rarely - weight gain.

Description of individual adverse reactions. Cases of itching (including intense itching) and/or urticaria have been reported following discontinuation of cetirizine use.

Adverse Reaction Alert

A system for reporting suspected adverse reactions after registration of a medicinal product is of great importance.

This allows continuous monitoring of the benefit/risk ratio of the drug.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms Symptoms observed with cetirizine overdose are mainly related to effects on the central nervous system or effects indicative of anticholinergic effects.

With a single dose of 50 mg, the following symptoms were observed: confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis, itching, anxiety, weakness, sedation, drowsiness, stupor, tachycardia, tremor, urinary retention.

Treatment. Immediately after taking the drug, gastric lavage or induction of vomiting. It is recommended to take activated carbon and carry out symptomatic and supportive therapy. There is no specific antidote. Hemodialysis is ineffective.

Interaction with other drugs

Based on the analysis of pharmacodynamics and pharmacokinetics of cetirizine, interaction with other drugs is unlikely.

There were no significant interactions observed with pseudoephedrine and theophylline (at a dose of 400 mg per day) in specific drug interaction studies.

The level of absorption of cetirizine is not reduced by food intake, but the rate of absorption is reduced.

Concomitant use of cetirizine with alcohol and other drugs that depress the central nervous system may further reduce concentration and reaction speed, although cetirizine does not enhance the effect of alcohol (at a blood concentration of 0.5 g/l).

If you are using the above or other medications (including over-the-counter medications), consult your doctor before using Cetirizine-Teva.

special instructions

In patients with spinal cord injury, prostatic hyperplasia, or other predisposing factors to urinary retention, caution is required as cetirizine may increase the risk of urinary retention.

In patients with renal failure, the dosage regimen of the drug should be adjusted (see section "Dosage and Administration").

Due to a possible decrease in renal function in elderly patients, the dosage regimen of the drug should be adjusted (see section "Dosage and Administration").

Caution is recommended when using cetirizine concomitantly with alcohol, as cetirizine may cause increased drowsiness.

Caution should be observed in patients with epilepsy and increased convulsive readiness.

Before prescribing allergy tests, a three-day “washing out” period is recommended due to the fact that H1-histamine receptor blockers inhibit the development of skin allergic reactions.

Cetirizine film-coated tablets should not be prescribed to patients with hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.

After stopping the use of cetirizine, itching and/or urticaria may occur, even if these symptoms were absent at the beginning of treatment. In some cases, symptoms may be severe and require resumption of cetirizine. Symptoms disappear when cetirizine is resumed.

Children.

Cetirizine film-coated tablets are contraindicated in children under 6 years of age, since this dosage form does not allow the use of an appropriate dosage for this age group.

Impact on the ability to drive vehicles and machinery

An objective assessment of the ability to drive vehicles and operate machinery did not reliably reveal any adverse events when taking the drug at the recommended dose. However, for patients with symptoms of drowsiness while taking the drug, it is advisable to refrain from driving a car, engaging in potentially hazardous activities, or operating machinery that requires increased concentration and speed of psychomotor reactions.

Release form

Film-coated tablets, 10 mg.

10 tablets in blisters made of PVC/PVDC/aluminum foil. 1, 2 or 3 blisters along with instructions for use are placed in a cardboard box, on which protective stickers can additionally be applied.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging to protect from light.

Keep out of the reach of children!

Best before date

3 years.

Do not use after the expiration date.

Vacation conditions

Available without a prescription.

Note!

Description of the drug Cetirizine-Teva table. p/o 10 mg No. 20 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.